Claims about PresVu eye drop false, unethical: DCGI

Explanation sought from pharma firm

Tribune News Service

New Delhi, Updated At : 07:27 AM Sep 06, 2024 IST

Photo for representational purpose only.

The claims made by ENTOD Pharmaceuticals that its product PresVu eye drops had been approved by Drug Controller General of India (DCGI) and that the drug offered spectacular treatment for presbyopia were unethical and false presentation of facts, a top official source said. A DGCI official said an explanation had been sought from the company.

“This is unethical and false presentation of facts. Explanation has been sought from the company,” a top source said.

ENTOD Pharmaceuticals had said: “PresVu is the first eye drop in India specifically developed to reduce dependency on reading glasses for individuals affected by presbyopia, a common age-related vision condition that typically impacts those over 40.”

Company CEO Nikkhil K Masurkar had claimed that PresVu was the result of years of dedicated research and development and it had secured DCGI’s approval.

Tags :

The Tribune, now published from Chandigarh, started publication on February 2, 1881, in Lahore (now in Pakistan). It was started by Sardar Dyal Singh Majithia, a public-spirited philanthropist, and is run by a trust comprising five eminent persons as trustees.

The Tribune, the largest selling English daily in North India, publishes news and views without any bias or prejudice of any kind. Restraint and moderation, rather than agitational language and partisanship, are the hallmarks of the newspaper. It is an independent newspaper in the real sense of the term.

The Tribune has two sister publications, Punjabi Tribune (in Punjabi) and Dainik Tribune (in Hindi).

Remembering Sardar Dyal Singh Majithia

Designed and developed by : SORTD

Suggested Articles